Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 10, 2012, Pages 1825-1831

  Kolasa Trela, Renata ^a   Fil, Korneliusz ^a   Bazanek, Marta ^a   Grudzień, Grzegorz ^a,b   Sobczyk, Dorota ^a   Sadowski, Jerzy ^a,b   Undas, Anetta ^a,b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Aortic valve stenosis; Inflammation; Lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN;

ADULT; AORTA VALVE STENOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; PATHOGENESIS; PRESSURE GRADIENT; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84867773641     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0015     Document Type: Article

References (32)

1. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-22.
2. Olszowska M. Pathogenesis and pathophysiology of aortic valve stenosis in adults. Pol Arch Med Wewn 2011;121:409-13.
3. Kolasa-Trela R, Miszalski-Jamka T, Grudzień G, Wypasek E, Kostkiewicz M. Adiponectin, leptin, and resistin in patients with aortic stenosis without concomitant atherosclerotic vascular disease. Pol Arch Med Wewn 2011;121:352-9.
4. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:527-32.
5. Mitsios JV, Vini MP, Stengel D, Ninio E, Tselepis AD. Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol 2006;26:1907-13.
6. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005;2:529-35.
7. Ahmed MS, Ji JZ, Meng QH. Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target? Inflamm Allergy Drug Targets 2011;10:236-46.
8. Khuseyinova N, Koenig W. Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A (2) fit in? Mol Diagn Ther 2007;11:203-17.
9. Ali M, Madjid M. Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol 2009;5:159-73.
10. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007;82:159-65.
11. 2 - a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med 2011;269:94-106.
12. Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol 2009;24:358-63.
13. Atik B, Johnston SC, Dean D. Association of carotid plaque Lp-PLA (2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke. PLoS One 2010;5:e11026.
14. Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A (2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J 2011;2:27-38.
15. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715-21.
16. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009;10:1-23.
17. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101:51-7.
18. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 2006;9:138-43.
19. Detopoulou P, Nomikos T, Fragopoulou E, Panagiotakos DB, Pitsavos C, Stefanadis C, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults. Lipids Health Dis 2009;8:19.
20. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new kid on the block. Clin Chem 2006;52:1645-50.
21. Rouleau L, Copland IB, Tardif JC, Mongrain R, Leask RL. Neutrophil adhesion on endothelial cells in a novel asymmetric stenosis model: effect of wall shear stress gradients. Ann Biomed Eng 2010;38:2791-804.
22. Turunen P, Puhakka H, Rutanen J, Hiltunen MO, Heikura T, Gruchala M, et al. Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis 2005;179:27-33.
23. Kastellanos SS, Toumpoulis IK, Aggeli C, Zezas S, Chlapoutakis E, Kastellanos S, et al. Time course of C-reactive protein, tumour necrosis factor-alpha and monocyte chemoattractant protein-1 following the surgical treatment of patients with aortic valve stenosis. Hellenic J Cardiol 2007;48:5-14.
24. Kupreishvili K, Baidoshvili A, ter Weeme M, Huybregts MA, Krijnen PA, Van Hinsbergh VW, et al. Degeneration and atherosclerosis inducing increased deposition of type IIA secretory phospholipase A2, C-reactive protein and complement in aortic valves cause neutrophilic granulocyte influx. J Heart Valve Dis 2011;20:29-36.
25. Côté C, Pibarot P, Després JP, Mohty D, Cartier A, Arsenault BJ, et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94:1175-80.
26. Onat A, Hergenç G, Can G, Uǧur M, Nartop F. Dual activity of serum lipoprotein-associated phospholipase A (2) yielding positive and inverse associations with cardiometabolic risk. Clin Chem Lab Med 2011;49:1349-57.
27. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol 1995;75:1189-95.
28. Teo KK, Corsi DJ, Tam JW, Dumesnil JG, Chan KL. Lipid lowering on progression of mild to moderate aortic stenosis: metaanalysis of the randomized placebo-controlled clinical trials on 2344 patients. Can J Cardiol 2011;27:800-8.
29. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 2008;199:110-5.
30. Yoshimura T, Ohshige A, Maeda T, Ito M, Okamura H. Estrogen replacement therapy decreases platelet-activating factoracetylhydrolase activity in post-menopausal women. Maturitas 1999;31:249-53.
31. Chauffe RJ, Wilensky RL, Mohler ER 3rd. Recent developments with lipoprotein-associated phospholipase A2 inhibitors. Curr Atheroscler Rep 2010;12:43-7.
32. Lp-PLA (2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.